Parexel

Executive Summary

Parexel is a global Contract Research Organization (CRO) that provides comprehensive drug development services, from early-stage portfolio optimization to post-approval lifecycle management. Founded in 1982 and headquartered in London, UK, the company leverages digital health and AI/machine learning to enhance clinical trial efficiency and operational excellence. As a privately held company, Parexel has built a strong reputation for its end-to-end solutions, serving biopharmaceutical clients worldwide. With a focus on innovation, Parexel integrates advanced analytics and real-world evidence to accelerate development timelines and improve patient outcomes. The company's extensive experience and global footprint position it as a key partner in the evolving pharmaceutical landscape, where demand for outsourced clinical services continues to grow.

Upcoming Catalysts (preview)

• H2 2026Launch of AI-Powered Clinical Trial Platform80% success
• 2026Major Multi-Year Contract Win with Top-20 Pharma60% success
• TBDStrategic Acquisition to Expand Digital Health Capabilities50% success